
Scinai Immunotherapeutics Ltd. (SCNI) Stock Ticker
SCNI right now
Market factors today
Unlock the full SCNI picture
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
SCNI stock facts
| Ticker symbol | SCNI |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $801,254 |
| CEO | Amir Reichman |
| Employees | 45 |
| Headquarters | Jerusalem, JM, IL |
| IPO date | 2015-05-11 |
| Website | www.scinai.com |
What you can see for SCNI on Tickr
Live SCNI price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SCNI report.
Rankings
FAQ
What is the ticker symbol for Scinai Immunotherapeutics Ltd.?
The ticker symbol for Scinai Immunotherapeutics Ltd. is SCNI, listed on the NASDAQ Capital Market.
What is SCNI?
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck…